These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 15949056)
1. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Anderson JR; Nawarskas JJ Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056 [TBL] [Abstract][Full Text] [Related]
2. Ranolazine: a potential new treatment for chronic stable angina. Anderson JR; Khou S; Nawarskas JJ Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803 [TBL] [Abstract][Full Text] [Related]
3. Ranolazine for the management of coronary artery disease. Cheng JW Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457 [TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA; J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870 [TBL] [Abstract][Full Text] [Related]
5. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders. Bhandari B; Subramanian L Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101 [TBL] [Abstract][Full Text] [Related]
6. Ranolazine: a new option in the management of chronic stable angina. Dobesh PP; Trujillo TC Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Rousseau MF; Pouleur H; Cocco G; Wolff AA Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536 [TBL] [Abstract][Full Text] [Related]
8. Ranolazine: a new approach to management of patients with angina. Tafreshi MJ; Fisher E Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572 [TBL] [Abstract][Full Text] [Related]
9. Ranolazine: new approach for the treatment of stable angina pectoris. Stanley WC Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027 [TBL] [Abstract][Full Text] [Related]
10. Ranolazine (Ranexa) for chronic stable angina. Ndegwa S Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750 [TBL] [Abstract][Full Text] [Related]
11. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Melloni C; Newby LK Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903 [TBL] [Abstract][Full Text] [Related]
12. Ranolazine: new drug. Stable angina: not worth the risk. Prescrire Int; 2009 Aug; 18(102):148-7. PubMed ID: 19743543 [TBL] [Abstract][Full Text] [Related]
14. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Wenger NK; Chaitman B; Vetrovec GW Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454 [TBL] [Abstract][Full Text] [Related]
15. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). Koren MJ; Crager MR; Sweeney M J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. Chaitman BR J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131 [TBL] [Abstract][Full Text] [Related]
17. Chronic angina: new medical options for treatment. McCullough PA Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688 [TBL] [Abstract][Full Text] [Related]
18. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401 [TBL] [Abstract][Full Text] [Related]